SENSOME

From Bio-Impedance to Clinical Insights

Sensome is developing medical technologies that will empower physicians with patient-specific information in real-time so they can make faster, more effective treatment decisions during minimally invasive procedures.
We have created a breakthrough microchip technology and proprietary integration processes that seamlessly embed tissue-sensing into a wide range of minimally invasive medical devices.
This new class of smart connected medical devices is designed to transform in situ bio-impedance measurements into real-time, easy-to-interpret insights, unlocking the promise of data-driven care in interventional medicine.

Real-time

Data-driven decisions when it matters most

Versatile

Easy integration across multiple applications

Insightful

Clear outputs for meaningful decisions

Pioneering Tissue-Sensing in Stroke

The Clotild® Smart Guidewire System (Clotild) is the first tissue-sensing neurovascular guidewire that will pioneer Sensome’s technology in the treatment of Acute Ischemic Stroke (AIS). Manufactured by world-renowned Asahi Intecc, Clotild is currently undergoing regulatory activities targeting commercialization in the EU, US and Japan.

Tissue-Sensing across indications

Tissue-sensing to guide AIS treatment

One in four people over the age of 25 will have a stroke during their lifetime. About a third of these patients suffer from an AIS eligible for endovascular treatment.
Today, physicians have very limited information guiding treatment decisions for fast and safe restoration of brain blood flow in these procedures, leaving patients at increased risk of death or permanent disability.
Clotild aims to provide physicians with real-time blood clot characterization supporting more informed treatment decisions.
We have demonstrated the capability of tissue-sensing for clot characterization in multiple peer-reviewed publications and successfully completed a first-in-human study. Clotild is advancing through regulatory processes toward commercialization in the EU, US, and Japan.

Regulatory stage Real-time clot characterization Neurovascular

Tissue-sensing to guide lung cancer biopsy

Lung cancer is the leading cause of cancer-related deaths worldwide, responsible for over 2 million deaths every year.
The diagnosis involves obtaining a tissue sample from a suspected lesion through biopsy, commonly performed during bronchoscopy. Early detection of lung cancer significantly improves patient survival and a failed biopsy can delay diagnosis. A real-time tool-in-lesion confirmation system can guide the bronchoscopy procedure to relevant biopsy sites, improving sampling yield, and accelerating diagnosis and treatment.
We have demonstrated in a clinical feasibility study that Sensome’s tissue-sensing technology can successfully be used to differentiate healthy lung from cancerous tissue in a biopsy procedure.

Clinical stage Real-time cancer detection Lung cancer

Tissue-sensing to guide Peripheral Vascular Intervention

Over 200 million people suffer from Peripheral Vascular Disease (PVD) worldwide. PVD primarily affects the blood vessels of the lower limbs and is associated with high risk of amputation, permanent disability and death. Understanding the makeup of the blockage of peripheral blood vessels is key to guiding interventional procedures leading to a safe and long-lasting reopening of these vessels.
We have demonstrated in a clinical feasibility study that Sensome’s tissue-sensing technology can detect the presence of fresh clot in blocked peripheral blood vessels.

Clinical stage Real-time fresh clot detection Peripheral vascular

These are just some examples of how our tissue-sensing technology can transform interventional procedures with clinically relevant data. If you would like to enhance your medical devices with our tissue-sensing technology and bring these smart connected medical devices to patients, get in touch!

SENSOME AT A GLANCE

Clotild^®: Understand the clot. Choose your first-pass.

Leading physicians in the neurovascular field share their expectations on how Clotild^® could transform endovascular treatment of acute ischemic stroke.

~7:30Neurovascular

Sensome’s tissue-sensing technology: bringing actionable real-time intra-procedural insights to the treatment of acute ischemic stroke and beyond.

Watch our CEO present Sensome’s vision and smart sensing technology platform. From a connected guidewire for the treatment of acute ischemic stroke to applications in lung cancer biopsies and peripheral vascular interventions. By adapting the world’s smallest impedance-based tissue sensor to minimally invasive devices, our technology aims to empower physicians to make data-driven, outcome-focused decisions right at the point of care in real-time.

~8:00Neurovascular, Peripheral Vascular, Lung cancer

OUR PARTNERS & ECOSYSTEM

We are proud to be supported by a strong ecosystem of investors, research institutions, strategic partners and innovation networks helping us to bring breakthrough medical devices to patients worldwide.